Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
JP6830578B2 - Autism spectrum disorder determination method, autism spectrum disorder determination kit and measurement data acquisition method - Google Patents
[go: Go Back, main page]

JP6830578B2 - Autism spectrum disorder determination method, autism spectrum disorder determination kit and measurement data acquisition method - Google Patents

Autism spectrum disorder determination method, autism spectrum disorder determination kit and measurement data acquisition method Download PDF

Info

Publication number
JP6830578B2
JP6830578B2 JP2016170479A JP2016170479A JP6830578B2 JP 6830578 B2 JP6830578 B2 JP 6830578B2 JP 2016170479 A JP2016170479 A JP 2016170479A JP 2016170479 A JP2016170479 A JP 2016170479A JP 6830578 B2 JP6830578 B2 JP 6830578B2
Authority
JP
Japan
Prior art keywords
scavenging activity
determination
value
active oxygen
spectrum disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016170479A
Other languages
Japanese (ja)
Other versions
JP2018033393A5 (en
JP2018033393A (en
Inventor
暁 平山
暁 平山
秀夫 松▲崎▼
秀夫 松▲崎▼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Fukui NUC
Tsukuba University of Technology NUC
Original Assignee
University of Fukui NUC
Tsukuba University of Technology NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Fukui NUC, Tsukuba University of Technology NUC filed Critical University of Fukui NUC
Priority to JP2016170479A priority Critical patent/JP6830578B2/en
Publication of JP2018033393A publication Critical patent/JP2018033393A/en
Publication of JP2018033393A5 publication Critical patent/JP2018033393A5/ja
Application granted granted Critical
Publication of JP6830578B2 publication Critical patent/JP6830578B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Description

本発明は、被験者由来の生体材料に含まれる活性酸素消去活性を測定することを特徴とする、自閉症スペクトラム障害の判定方法および判定用キットに関する。 The present invention relates to a method for determining autism spectrum disorder and a kit for determining an autism spectrum disorder, which comprises measuring the active oxygen scavenging activity contained in a biomaterial derived from a subject.

自閉症スペクトラム障害(Autistic Spectrum Disorder、以下単にASDと称する。)とは、従来、自閉性障害、アスペルガー障害、小児崩壊性障害、レット障害、特定不能の5つの広汎性発達障害を、2013年5月に発表された米国精神医学会診断基準の改訂第5版(DSM−5)にて、遺伝要因が明確であるレット障害を除いた4つを一つの連続した包括概念として新たに分類した名称である。コミュニケーション能力や社会性、想像性、さらに行動・興味・活動における限定的かつ反復的なパターンに特異が観察される。欧米ではおよそ68人に1人がASDと報告され、頻度の高い発達障害である。ASDを含む発達障害に対する「療育」の開始時期は早い方が効果的であり、ASDの症状が初めて現れる2歳前後から就学までに「療育」を開始できることが好ましい。 Autistic Spectrum Disorder (hereinafter referred to simply as ASD) refers to five pervasive developmental disorders that have traditionally been autistic disorder, Asperger's disorder, pediatric disintegration disorder, let's disorder, and unspecified. In the 5th revised edition (DSM-5) of the American Psychiatric Association Diagnostic Criteria announced in May, the four categories excluding Let's disorder, whose genetic factors are clear, were newly classified as one continuous comprehensive concept. It is a name. Peculiarities are observed in communication skills, sociality, imagination, and limited and repetitive patterns in behavior, interests, and activities. In Europe and the United States, about 1 in 68 people is reported to have ASD, which is a frequent developmental disorder. It is effective to start "rehabilitation" for developmental disorders including ASD earlier, and it is preferable to be able to start "rehabilitation" from around 2 years old when the symptoms of ASD first appear to school.

現在、ASDの診断にはDSM−5における診断基準が用いられている。この基準は、社会的コミュニケーションおよび相互関係における持続的障害や限定された反復する様式の行動、興味、活動等の観察に基づくものであり、客観的・生物学的な審査判定基準ではない。また、未就学児は本来言語表現等も未発達であり、児童精神医学に関する豊富な経験を有する医師による高度に専門的な判断が要求されるため、ASDの早期発見を困難にする一因となっている。 Currently, the diagnostic criteria in DSM-5 are used for the diagnosis of ASD. This criterion is based on observations of persistent obstacles in social communication and interrelationships and limited repetitive behaviors, interests, activities, etc., and is not an objective or biological examination criterion. In addition, preschoolers are originally underdeveloped in language expression, etc., and highly specialized judgment is required by doctors with abundant experience in child and adolescent psychiatry, which is one of the factors that make early detection of ASD difficult. It has become.

ASDの早期発見のため、母親由来の生物試料に含まれる特定バイオマーカーへの抗体を指標とする方法も開発されている。具体的には、当該生物試料に含まれる、乳酸脱水素酵素、グアニン脱アミノ酵素、コラプシン反応媒介タンパク質1、ジヒドロピリミジナーゼ様タンパク質2、ストレス誘導性リンタンパク質1、及びYボックス結合タンパク質1からなる群から選択される1以上のポリペプチドへの抗体を指標とするものであり、当該母親が生む胎児がASDを発症する可能性を決定することができるという(特許文献1)。 For early detection of ASD, a method using an antibody against a specific biomarker contained in a biological sample derived from a mother as an index has also been developed. Specifically, from lactate dehydrogenase, guanine deaminoenzyme, collapsin reaction-mediated protein 1, dihydropyrimidinase-like protein 2, stress-induced phosphoprotein 1, and Y-box binding protein 1 contained in the biological sample. An antibody against one or more polypeptides selected from the above group is used as an index, and it is possible to determine the possibility that a fetus born by the mother will develop ASD (Patent Document 1).

また、ASDの原因を、乳幼児期の酸化ストレスや活性酸素消去活性の異常と結びつける報告もある(非特許文献1)。酸化ストレスの異常として、(1)グルタチオン系の異常に関し、グルタチオンの減少、その代謝関連酵素であるグルタチオンペルオキシダーゼの活性低下、その代謝関連物質であるメチオニンおよびシステインの減少、酸化型グルタチオンの増加、(2)メチレンテトラヒドロフォレートレダクターゼ遺伝子(MTHFR)におけるC677Tアレルの異常、(3)ビタミンA、ビタミンB6、ビタミンC、ビタミンD、ビタミンEの異常があるという。 There is also a report that the cause of ASD is linked to oxidative stress in infancy and abnormalities in active oxygen scavenging activity (Non-Patent Document 1). Abnormalities of oxidative stress include (1) decrease in glutathione, decrease in activity of glutathione peroxidase, which is a metabolism-related enzyme, decrease in methionine and cysteine, which are metabolism-related substances, and increase in oxidized glutathione, regarding (1) glutathione system abnormality. It is said that there are 2) abnormalities in C677T allele in the methylenetetrahydrofolate reductase gene (MTHR), and (3) abnormalities in vitamin A, vitamin B6, vitamin C, vitamin D, and vitamin E.

特許第5823964号公報Japanese Patent No. 5823964

Frustaci A,etc. ”Oxidative stress−related biomarkers in autism: systematic review and meta−analyses.”Free Rad. Biol. Med. Vol.52(2012),p2128−2141Frustaci A, etc. "Oxidative stress-related biomarkers in analysis: systematic review and meta-analysis." Free Rad. Biol. Med. Vol. 52 (2012), p2128-2141 玉田紘太等、「自閉症ヒト型モデルマウスの開発」、2011年、生化学第83巻第9号、p841−845Kota Tamada et al., "Development of Human Model Mouse for Autism", 2011, Biochemistry Vol. 83, No. 9, p841-845

特許文献1に示す方法は、妊娠の有無にかかわらずある女性がASD児を出産する可能性を推定するものであり、その女性が産んだ子供が実際にASDであるか否かを判定するものではない。ASDの臨床診断について、社会的コミュニケーションや相互関係の持続性などの観察のみに依拠した判定法に依存すると、言語能力の発達が十分でない乳幼児のASDの早期発見に対応できない場合が生じる。また、聴覚障碍者や視覚障碍者によるASDの診断が困難となる場合がある。したがって、生体材料を使用し、客観的にASD罹患の可能性を判定しうる方法の開発があれば、聴覚障碍者や視覚障碍者によるASDの判定が可能となり、便宜である。 The method shown in Patent Document 1 estimates the possibility that a woman gives birth to an ASD child regardless of whether or not she is pregnant, and determines whether or not the child born by the woman actually has ASD. is not it. If the clinical diagnosis of ASD relies solely on observations such as social communication and persistence of interrelationships, it may not be possible to respond to early detection of ASD in infants with insufficient language ability development. In addition, it may be difficult for a hearing-impaired person or a visually-impaired person to diagnose ASD. Therefore, if there is a development of a method capable of objectively determining the possibility of suffering from ASD using a biomaterial, it is possible for a hearing-impaired person or a visually impaired person to determine ASD, which is convenient.

また、非特許文献1に示すように、ASDを酸化ストレスと結びつける報告もあるが、活性酸素消去活性に基づいてASD罹患可能性を判定する方法は存在しない。活性酸素には、ヒドロキシラジカル、スーパーオキシド、アルコキシラジカル、ペルオキシラジカル、一重項酸素等があり、特にラジカルの測定は容易でないという問題もある。複雑な酸化ストレス関連反応を多元的に評価することは容易でなく、臨床診断として用いることができるような十分な感度や特異度、尤度比の特定も困難だからである。したがって、各種活性酸素消去能とASDとの関連を明らかにし、対象由来の生体材料の各種活性酸素の消去活性に基づき、簡便にASD罹患可能性を判定しうる方法の開発が望まれる。 Further, as shown in Non-Patent Document 1, there is a report that ASD is associated with oxidative stress, but there is no method for determining the possibility of ASD morbidity based on active oxygen scavenging activity. Active oxygen includes hydroxyl radical, superoxide, alkoxy radical, peroxy radical, singlet oxygen and the like, and there is also a problem that it is not easy to measure radicals in particular. This is because it is not easy to evaluate complex oxidative stress-related reactions in multiple ways, and it is also difficult to specify sufficient sensitivity, specificity, and likelihood ratio that can be used for clinical diagnosis. Therefore, it is desired to develop a method for clarifying the relationship between various active oxygen scavenging abilities and ASD and easily determining the possibility of ASD morbidity based on the scavenging activity of various active oxygens of the biomaterial derived from the subject.

また、被験者由来の生体材料の各種活性酸素の消去活性に基づき、簡便にASD罹患可能性を判定しうる方法、および判定用キットの開発が望まれる。 Further, it is desired to develop a method capable of easily determining the possibility of ASD morbidity based on the scavenging activity of various active oxygens of the biomaterial derived from the subject, and a determination kit.

本発明は上記事情に鑑みなされたもので、被験者の生体材料に含まれる活性酸素消去活性を指標にしたASD罹患可能性の判定方法を提供することを目的とする。 The present invention has been made in view of the above circumstances, and an object of the present invention is to provide a method for determining the possibility of ASD morbidity using the active oxygen scavenging activity contained in the biomaterial of a subject as an index.

また、ASDの判定用キットを提供することを目的とする。 Another object of the present invention is to provide a kit for determining ASD.

本発明は、電子スピン共鳴によるスピントラップ法によれば、対象由来の生体材料に含まれるヒドロキシラジカル、アルコキシラジカル、スーパーオキシド、アルコキシラジカル、ヒドロキシラジカル、ペルオキシラジカル、一重項酸素などの活性酸素種の消去活性の測定が可能であること、これら測定値とASD罹患者との間に一定の関係があることを見出し、本発明を完成させた。 According to the spin trap method by electron spin resonance, the present invention relates to active oxygen species such as hydroxyl radical, alkoxy radical, superoxide, alkoxy radical, hydroxyl radical, peroxy radical, and singlet oxygen contained in the biological material derived from the object. We have found that it is possible to measure scavenging activity and that there is a certain relationship between these measured values and ASD-affected persons, and completed the present invention.

すなわち、本発明の第1の観点に係るASDの判定方法は、対象由来の生体材料のヒドロキシラジカル消去活性、スーパーオキシド消去活性およびアルコキシラジカル消去活性からなる群より選択される少なくとも2以上の活性酸素消去活性の測定値を、前記各活性酸素消去活性に対応する判定値と比較し、当該比較結果に基づき、前記対象がASDに罹患している可能性を求める判定工程を含み、前記判定工程では、前記比較結果が、以下に列記する判定要件、
前記ヒドロキシラジカル消去活性の測定値を含む場合、当該測定値が前記ヒドロキシラジカル消去活性の判定値未満であるという第1の判定要件、
前記スーパーオキシド消去活性の測定値を含む場合、当該測定値が前記スーパーオキシド消去活性の判定値以上であるという第2の判定要件、および
前記アルコキシラジカル消去活性の測定値を含む場合、当該測定値が前記アルコキシラジカル消去活性の判定値以上であるという第3の判定要件、を満たすか否かを示すものであり、
前記第1の判定要件、第2の判定要件および第3の判定要件のいずれか2つ以上満たす場合に前記対象はASDに罹患している可能性ありと判定するものであり、
前記判定値は、定型発達群およびASD群での前記活性酸素消去活性の測定値に基づき予め決定され、前記定型発達群と前記ASD群とで統計的有意差がある場合はカットオフ値とし、
前記ASD群と前記定型発達群との間に統計的有意差が無い場合は所定の信頼区間を設定し同等性検定を行い、優越性が無く同等性を示す上限値と下限値をそれぞれ判定値とすることを特徴とする。
That is, the method for determining ASD according to the first aspect of the present invention is at least two or more active oxygens selected from the group consisting of hydroxyl radical scavenging activity, superoxide scavenging activity and alkoxy radical scavenging activity of the biological material derived from the subject. measurements of scavenging activity, the comparison with the determination values corresponding to the active oxygen scavenging activity, based on the comparison result, seen including a determination step of determining the likelihood that said subject is suffering from ASD, the determining step Then, the above comparison result is the judgment requirement listed below.
When the measured value of the hydroxyl radical scavenging activity is included, the first determination requirement that the measured value is less than the determination value of the hydroxyl radical scavenging activity,
When the measured value of the superoxide scavenging activity is included, the second determination requirement that the measured value is equal to or higher than the determination value of the superoxide scavenging activity, and
When the measurement value of the alkoxy radical scavenging activity is included, it indicates whether or not the third determination requirement that the measurement value is equal to or higher than the determination value of the alkoxy radical scavenging activity is satisfied.
When any two or more of the first determination requirement, the second determination requirement, and the third determination requirement are satisfied, it is determined that the subject may be suffering from ASD.
The determination value is determined in advance based on the measured values of the active oxygen scavenging activity in the typical development group and the ASD group, and if there is a statistically significant difference between the typical development group and the ASD group, it is set as a cutoff value.
If there is no statistically significant difference between the ASD group and the neurotypical development group, a predetermined confidence interval is set and an equivalence test is performed, and the upper and lower limits indicating equivalence without superiority are determined respectively. characterized by a.

また、前記活性酸素消去活性が、ペルオキシラジカル消去活性および/または一重項酸素消去活性をさらに含み、前記判定工程は、更に、前記ペルオキシラジカル消去活性の測定値を含む場合、当該測定値が前記ペルオキシラジカル消去活性の2つの判定値の間にあるという第4の判定要件、および/または、前記一重項酸素消去活性の測定値を含む場合、当該測定値が前記一重項酸素消去活性の2つの判定値の間にあるという第5の判定要件を含み、
前記第4の判定要件または前記第5の判定要件を満たす場合に前記対象はASDに罹患している可能性がより高いと判定することを特徴とする。
Moreover, the active oxygen scavenging activity further seen containing a peroxy radical scavenging activity and / or singlet oxygen scavenging activity, the determining step further, if it contains a measure of the peroxy radical scavenging activity, the measurement value is the If the fourth determination requirement that the peroxy radical scavenging activity is between the two determination values and / or the measurement value of the singlet oxygen scavenging activity is included, the measurement value is the two determination values of the singlet oxygen scavenging activity. Including the fifth judgment requirement that it is between the judgment values,
When the fourth determination requirement or the fifth determination requirement is satisfied, the subject is determined to be more likely to have ASD .

前記判定工程は前記各活性酸素消去活性の前記測定値を、対応する1つ以上の前記判定値と比較し、当該比較結果に基づいて前記各活性酸素消去活性にスコアを割り付け、ASDへの罹患可能性を前記スコアの合計値として求めることを特徴とする。 Wherein as the determination Engineering is the measured value of the respective active oxygen scavenging activity, as compared to the corresponding one or more of the decision value, allocating a score to each of the active oxygen scavenging activity on the basis of the comparison result, the ASD It is characterized in that the susceptibility to morbidity is obtained as the total value of the scores .

また、前記各活性酸素消去活性は、電子スピン共鳴によるスピントラップ法で測定されることを特徴とする。 Further, each active oxygen scavenging activity is measured by a spin trap method by electron spin resonance.

本発明の第2の観点に係るASDの判定用キットは、過酸化水素、リボフラビン、および2,2’−アゾビス[2−アミノジプロパン]ジヒドロクロライドからなる群から選択される2以上の活性酸素発生剤と、スピントラップ剤とを、対象由来の生体材料に含まれる活性酸素消去活性の測定試薬として含むことを特徴とする。 The kit for determining ASD according to the second aspect of the present invention comprises two or more active oxygen species selected from the group consisting of hydrogen peroxide, riboflavin, and 2,2'-azobis [2-aminodipropane] dihydrochloride. It is characterized by containing a generator and a spin trap agent as a reagent for measuring active oxygen scavenging activity contained in a biomaterial derived from a subject .

本発明の第の観点に係る測定データ取得方法は、対象由来の生体材料のヒドロキシラジカル消去活性、スーパーオキシド消去活性およびアルコキシラジカル消去活性からなる群より選択される少なくとも2以上の活性酸素消去活性、およびペルオキシラジカル消去活性および/または一重項酸素消去活性の活性酸素消去活性の測定値を、前記各活性酸素消去活性に対応する判定値と比較し、当該比較結果に基づき、前記対象がASDに罹患している可能性を求めるための測定データ処理工程を含み、
前記測定データ処理工程では、前記比較結果が、以下に列記する条件、
前記ヒドロキシラジカル消去活性の測定値を含む場合、当該測定値が前記ヒドロキシラジカル消去活性の判定値未満であるという第1の条件、
前記スーパーオキシド消去活性の測定値を含む場合、当該測定値が前記スーパーオキシド消去活性の判定値以上であるという第2の条件、
前記アルコキシラジカル消去活性の測定値を含む場合、当該測定値が前記アルコキシラジカル消去活性の判定値以上であるという第3の条件、
前記ペルオキシラジカル消去活性の測定値を含む場合、当該測定値が前記ペルオキシラジカル消去活性の2つの判定値の間にあるという第4の条件、および/または、
前記一重項酸素消去活性の測定値を含む場合、当該測定値が前記一重項酸素消去活性の2つの判定値の間にあるという第5の条件を含み、
前記第1の条件、第2の条件および第3の条件のいずれか2つ以上満たし、且つ、前記第4の条件または前記第5の条件を満たす場合に前記対象はASDに罹患している可能性が高いと判定するための測定データ取得方法であって、
前記判定値は、定型発達群およびASD群での前記活性酸素消去活性の測定値に基づき予め決定され、前記定型発達群と前記ASD群とで統計的有意差がある場合はカットオフ値とし、
前記ASD群と前記定型発達群との間に統計的有意差が無い場合は所定の信頼区間を設定し同等性検定を行い、優越性が無く同等性を示す上限値と下限値をそれぞれ判定値とすることを特徴とする。
The measurement data acquisition method according to the third aspect of the present invention has at least two or more active oxygen scavenging activities selected from the group consisting of hydroxyl radical scavenging activity, superoxide scavenging activity and alkoxy radical scavenging activity of the biological material derived from the subject. , And the measured values of the active oxygen scavenging activity of the peroxyradical scavenging activity and / or the single-term oxygen scavenging activity are compared with the determination values corresponding to the respective active oxygen scavenging activities, and based on the comparison result, the subject becomes ASD. Includes measurement data processing steps to determine possible morbidity
In the measurement data processing step, the comparison results are based on the conditions listed below.
When the measured value of the hydroxyl radical scavenging activity is included, the first condition that the measured value is less than the determination value of the hydroxyl radical scavenging activity,
When the measured value of the superoxide scavenging activity is included, the second condition that the measured value is equal to or higher than the determination value of the superoxide scavenging activity.
When the measured value of the alkoxy radical scavenging activity is included, the third condition that the measured value is equal to or higher than the determination value of the alkoxy radical scavenging activity.
When the measured value of the peroxy radical scavenging activity is included, the fourth condition that the measured value is between the two determination values of the peroxy radical scavenging activity, and / or
When the measured value of the singlet oxygen scavenging activity is included, the fifth condition that the measured value is between the two determination values of the singlet oxygen scavenging activity is included.
The subject may be suffering from ASD if any two or more of the first condition, the second condition and the third condition are satisfied, and if the fourth condition or the fifth condition is satisfied. It is a measurement data acquisition method for determining that the property is high.
The determination value is determined in advance based on the measured values of the active oxygen scavenging activity in the typical development group and the ASD group, and if there is a statistically significant difference between the typical development group and the ASD group, it is set as a cutoff value.
If there is no statistically significant difference between the ASD group and the neurotypical development group, a predetermined confidence interval is set and an equivalence test is performed, and the upper and lower limits indicating equivalence without superiority are determined respectively. characterized by a.

本発明によれば、対象に由来する生体材料に含まる複数の活性酸素消去能を測定し、予め設定した判定値と比較することで、客観的にASDの罹患可能性を判定することができる。 According to the present invention, the possibility of ASD can be objectively determined by measuring a plurality of active oxygen scavenging abilities contained in a biomaterial derived from a subject and comparing them with preset determination values. ..

実施例1で測定した各種活性酸素消去活性の定型発達群とASD群との群間比較を示す図である。It is a figure which shows the comparison between the typical development group of various active oxygen scavenging activity measured in Example 1 and the ASD group. 実施例1で統計的有意差が検出された、ヒドロキシラジカル、アルコキシラジカル、スーパーオキシドの事前確率と事後確率との関係を示す図である。It is a figure which shows the relationship between the prior probability and posterior probability of hydroxyl radical, alkoxy radical, and superoxide in which a statistically significant difference was detected in Example 1.

以下、本発明を詳細に説明する。
(1)活性酸素消去活性の測定
本発明に係るASDの判定方法では、各活性酸素消去活性の測定値を使用する。活性酸素とは、酸素がより反応性の高い分子種であるスーパーオキシド、過酸化水素、ヒドロキシルラジカル、一重項酸素などに変化した場合の呼称である。フリーラジカルとは不対電子を有する分子のことをいい、スーパーオキシドやヒドロキシルラジカルなどがある。活性酸素消去活性として、ヒドロキシラジカル消去活性、アルコキシラジカル消去活性、スーパーオキシド消去活性がある。更に、ペルオキシラジカル消去活性および/または一重項酸素消去活性を測定することが好ましい。活性酸素種は反応性が高く、常温常圧では安定に存在する時間(寿命)が短いが、電子スピン共鳴装置(Electron Spin Resonance:以下、単にESRと称する)を用いたスピントラップ法で測定することができる。一定量の活性酸素が生成できる溶液に試料を加え、発生する活性酸素量が減少すれば活性酸素消去活性ありと評価することができる。
Hereinafter, the present invention will be described in detail.
(1) Measurement of active oxygen scavenging activity In the method for determining ASD according to the present invention, the measured value of each active oxygen scavenging activity is used. Reactive oxygen is a name when oxygen is changed to a more reactive molecular species such as superoxide, hydrogen peroxide, hydroxyl radical, and singlet oxygen. Free radicals are molecules that have unpaired electrons, such as superoxide and hydroxyl radicals. Active oxygen scavenging activity includes hydroxyl radical scavenging activity, alkoxy radical scavenging activity, and superoxide scavenging activity. Furthermore, it is preferable to measure the peroxy radical scavenging activity and / or the singlet oxygen scavenging activity. Reactive oxygen species are highly reactive and have a short stable existence time (life) at normal temperature and pressure, but they are measured by the spin trap method using an electron spin resonance device (hereinafter, simply referred to as ESR). be able to. A sample is added to a solution capable of generating a certain amount of active oxygen, and if the amount of active oxygen generated decreases, it can be evaluated as having active oxygen scavenging activity.

ESRスピントラップ法では、試料に、活性酸素種を安定で長寿命のフリーラジカルに変換するためのスピントラップ剤を添加する。スピントラップ剤が不安定な活性酸素と反応してより安定なフリーラジカルであるスピンアダクトを生成し、ESRによる検出が可能となる。例えば、使用できるスピントラップ剤としてCYPMPO(5-(2,2-dimethyl-1,3-propoxycyclophosphoryl)-5-methyl-1-pyrroline-N-oxide)がある。CYPMPOを用いると、ヒドロキシルラジカル、スーパーオキシド、アルコキシラジカルおよびペルオキシラジカルなどがCYPMPOと反応し、それぞれのスピンアダクトを生成する。スピンアダクトのESRスペクトルの特性から活性酸素種を区別し、かつそれらの消去活性を定量することができる。このように、ESRを用いれば、フリーラジカルの有無の確認と定量が可能である。また、一重項酸素はフリーラジカルではないが、スピントラップ剤として4-hydroxy-2,2,6,6-tetramethylpiperidine(以下、4−OH−TEMPと称す。)を用いることにより、ESRを用いて定量が可能である。本発明の活性酸素消去活性の測定で使用できるスピントラップ剤は、不安定なフリーラジカルや一重項酸素から安定なスピンアダクトを生成できれば、上記に限定されるものではない。また、活性酸素発生剤も特に限定されるものではない。 In the ESR spin trap method, a spin trap agent for converting reactive oxygen species into stable and long-lived free radicals is added to the sample. The spin trap agent reacts with unstable active oxygen to generate spin adduct, which is a more stable free radical, and can be detected by ESR. For example, there is CYPMPO (5- (2,2-dimethyl-1,3-propoxycyclophosphoryl) -5-methyl-1-pyrroline-N-oxide) as a spin trapping agent that can be used. When CYPMPO is used, hydroxyl radicals, superoxides, alkoxy radicals, peroxy radicals and the like react with CYPMPO to generate their respective spin adducts. Reactive oxygen species can be distinguished from the characteristics of the ESR spectrum of spin adduct, and their scavenging activity can be quantified. In this way, the presence or absence of free radicals can be confirmed and quantified by using ESR. In addition, although singlet oxygen is not a free radical, ESR is used by using 4-hydroxy-2,2,6,6-tetramethylpiperidine (hereinafter referred to as 4-OH-TEMP) as a spin trapping agent. Quantification is possible. The spin trapping agent that can be used for measuring the active oxygen scavenging activity of the present invention is not limited to the above as long as a stable spin adduct can be generated from unstable free radicals and singlet oxygen. Further, the active oxygen generator is not particularly limited.

活性酸素の消去活性は、所定の抗酸化物質による消去活性の相当量で評価することができる。例として、ヒドロキシラジカル消去活性測定法を下記に示す。試料を含有しないフリーラジカル生成溶液に含まれるヒドロキシラジカル由来のスピンアダクトのピーク高さ(I0)を定量し、次いで、前記フリーラジカル生成溶液に試料を添加して同様にヒドロキシラジカル由来のスピンアダクトのピーク高さ(IS)を定量し、I0/(IS−1)を算出すれば、ヒドロキシラジカル消去活性比を得ることができる。一方、予めサンプルに代えて測定する活性酸素に対して特異性の高い抗酸化物質(本例示の場合はグルタチオン(以下、GSHと称す。)がこれに相当する)を用いて、上記と同様に操作してGSH量とヒドロキシラジカル消去活性比の検量線を作成しておく。この検量線を用いれば、サンプルのヒドロキシラジカル消去活性比をGSH相当量として算出することができる。このようにして得られたGSH相当量を、「ヒドロキシラジカル消去活性」とする。他の活性酸素消去活性も、対応する消去活性評価物質の相当量を算出し、消去活性とする。 The scavenging activity of active oxygen can be evaluated by a considerable amount of scavenging activity by a predetermined antioxidant. As an example, a method for measuring hydroxyl radical scavenging activity is shown below. The peak height (I0) of the hydroxyl radical-derived spin adduct contained in the free radical generation solution containing no sample is quantified, and then the sample is added to the free radical generation solution to similarly obtain the hydroxyl radical-derived spin adduct. The hydroxyl radical scavenging activity ratio can be obtained by quantifying the peak height (IS) and calculating I0 / (IS-1). On the other hand, using an antioxidant having high specificity for active oxygen to be measured in advance instead of the sample (glutathione (hereinafter referred to as GSH) corresponds to this in this example), the same as above. Manipulate to prepare a calibration curve of GSH amount and hydroxyl radical scavenging activity ratio. By using this calibration curve, the hydroxyl radical scavenging activity ratio of the sample can be calculated as a GSH equivalent amount. The amount equivalent to GSH thus obtained is referred to as "hydroxy radical scavenging activity". For other active oxygen scavenging activities, a corresponding amount of the corresponding scavenging activity evaluator is calculated and used as the scavenging activity.

ESRスピントラップ法では、活性酸素を発生させる物質を変更することで、特定の活性酸素種を生成させることができる。例えば、ヒドロキシラジカルを生成するために、過酸化水素と紫外光の照射を組み合わせることができる。このような物質や電磁波の種類は、各活性酸素に応じて適宜選択することができる。また、検量線作成に使用するGSHなどの消去活性評価物質も、各活性酸素表比活性の定量性が確保できればよく、特に制限はない。消去活性評価物質として、GSHの他、スーパーオキシド不均化酵素(以下、SODと称す)、トロロクス、α−リポ酸などを使用することができる。 In the ESR spin trap method, a specific active oxygen species can be generated by changing the substance that generates active oxygen. For example, hydrogen peroxide and ultraviolet light irradiation can be combined to generate hydroxyl radicals. The type of such a substance or electromagnetic wave can be appropriately selected according to each active oxygen. Further, the scavenging activity evaluation substance such as GSH used for preparing the calibration curve is not particularly limited as long as the quantitativeness of each active oxygen surface specific activity can be ensured. As the scavenging activity evaluator, in addition to GSH, superoxide dismutase (hereinafter referred to as SOD), trolox, α-lipoic acid and the like can be used.

(2)判定値
「判定値」とは、対象の活性酸素消去活性の測定値を所定の区分に割り振るための数値である。活性酸素消去活性毎に1個以上を設定することができる。
(2) Judgment value The "judgment value" is a numerical value for allocating the measured value of the target active oxygen scavenging activity to a predetermined category. One or more can be set for each active oxygen scavenging activity.

定型発達群とASD群のヒドロキシラジカル消去活性を比較したところ、後記する実施例1に示すように、ASD群はp<0.05の統計的有意差で定型発達群より低値であった。一方、スーパーオキシド消去活性は、p<0.01の統計的有意差で定型発達群より高値であり、アルコキシラジカル消去活性も、p<0.05の統計的有意差で定型発達群より高値であった。更に、ペルオキシラジカル消去活性や一重項酸素消去活性について定型発達群とASD群との群間比較を行ったところ、ペルオキシラジカル消去活性および一重項酸素消去活性は定型発達群とp<0.05の統計的有意差は検出されなかったが、所定範囲で同等性が認められた。そこで、各種活性酸素消去活性を指標とするASD罹患の判定が可能であるかを検討したところ、活性酸素消去活性毎に判定値を設定し、測定値を判定値で区分することで、ASDの罹患可能性を判定しうることが判明した。 When the hydroxyl radical scavenging activity of the typical development group and the ASD group was compared, as shown in Example 1 described later, the ASD group had a statistically significant difference of p <0.05, which was lower than that of the typical development group. On the other hand, the superoxide scavenging activity was higher than that of the neurotypical development group with a statistically significant difference of p <0.01, and the alkoxy radical scavenging activity was also higher than that of the neurotypical development group with a statistically significant difference of p <0.05. there were. Furthermore, when the peroxyradical scavenging activity and the singlet oxygen scavenging activity were compared between the typical development group and the ASD group, the peroxyradical scavenging activity and the singlet oxygen scavenging activity were p <0.05 with the typical development group. No statistically significant difference was detected, but equivalence was observed within a predetermined range. Therefore, when it was examined whether it is possible to determine ASD morbidity using various active oxygen scavenging activities as indicators, a determination value was set for each active oxygen scavenging activity, and the measured values were classified by the determination value to determine ASD. It has been found that the likelihood of morbidity can be determined.

(3)判定要件を用いた判定
本方法は、対象由来の測定値と判定値とを比較し、その比較結果に基づき、対象がASDに罹患している可能性を求める判定工程を含む。判定工程では、比較結果が、(i)対象のヒドロキシラジカル消去活性の測定値がヒドロキシラジカル消去活性の判定値未満という第1の判定要件、(ii)対象のスーパーオキシド消去活性の測定値がスーパーオキシド消去活性の判定値以上という第2の判定要件、(iii)対象のアルコキシラジカル消去活性の測定値がアルコキシラジカル消去活性の判定値以上という第3の判定要件の、いずれか2つ以上満たす場合に前記対象はASDに罹患している可能性ありと判定する。上記第1〜第3の判定要件に加え、(iv)ペルオキシラジカル消去活性の測定値を含む場合には、対象の測定値がペルオキシラジカル消去活性の2つの判定値の間にあるという第4の判定要件、および(v)一重項酸素消去活性の測定値を含む場合には、対象の測定値が一重項酸素消去活性の2つの判定値の間にあるという第5の判定要件の、いずれか1つ以上満たす場合に、より高確率でASDに罹患している可能性が高いと判断する。
(3) Judgment using judgment requirements This method includes a judgment step of comparing a measured value derived from a target with a judgment value and determining the possibility that the target has ASD based on the comparison result. In the determination step, the comparison result is (i) the first determination requirement that the measured value of the hydroxyl radical scavenging activity of the target is less than the determination value of the hydroxyl radical scavenging activity, and (ii) the measured value of the superoxide scavenging activity of the target is super. When any two or more of the second judgment requirement that the judgment value of the oxide scavenging activity or more and the third judgment requirement that the measured value of the alkoxy radical scavenging activity of the target (iii) is equal to or more than the judgment value of the alkoxy radical scavenging activity are satisfied. It is determined that the subject may have ASD. In addition to the above-mentioned first to third determination requirements, when (iv) a measurement value of peroxy radical scavenging activity is included, a fourth determination that the measurement value of the target is between the two determination values of peroxy radical scavenging activity. One of the judgment requirements and (v) a fifth judgment requirement that the measured value of the target is between the two judgment values of the singlet oxygen scavenging activity when the measurement value of the singlet oxygen scavenging activity is included. If one or more are satisfied, it is judged that there is a high possibility of having ASD.

上記判定要件に使用する判定値は、ASD群由来の生体材料と、定型発達群由来の生体材料についてそれぞれ各活性酸素消去活性を測定し、その測定値が定型発達群とASD群とで統計的有意差がある場合はカットオフ値を求め、これを判定値とすることができる。また、ASD群と定型発達群との間に統計的有意差が無い場合は、所定の信頼区間を設定し同等性検定を行い、優越性が無く同等性を示す上限値と下限値をそれぞれ判定値として用いることができる。例えば、両群の95%信頼区間などを元に同等とみなす区間を設定し、この区間を用いてある対象の活性酸素消去活性が同等であるか否かを判定してもよい。同等とみなす区間は、任意に設定できるが、例えば、定型発達群とASD群の95%信頼区間全体を所定のマージンを挟んで含む区間や、定型発達群とASD群を一群とした時の平均値±2SDを上限値及び下限値とする区間などに設定してもよい。これ以外に、各活性酸素消去活性の測定値に基づいてASD罹患可能性を判定できるのであれば、他の方法を用いて判定値を設定してもよい。 The judgment values used for the above judgment requirements are those obtained by measuring the active oxygen scavenging activity of each of the biomaterial derived from the ASD group and the biomaterial derived from the typical development group, and the measured values are statistical for the typical development group and the ASD group. If there is a significant difference, the cutoff value can be obtained and used as the determination value. If there is no statistically significant difference between the ASD group and the neurotypical development group, a predetermined confidence interval is set and an equivalence test is performed to determine the upper and lower limits that show equivalence without superiority. It can be used as a value. For example, a section to be regarded as equivalent may be set based on the 95% confidence interval of both groups, and this section may be used to determine whether or not the active oxygen scavenging activity of a subject is equivalent. The sections considered to be equivalent can be set arbitrarily, but for example, a section including the entire 95% confidence interval of the typical development group and the ASD group with a predetermined margin, or an average when the typical development group and the ASD group are grouped together. The value ± 2SD may be set as an upper limit value and a lower limit value. In addition to this, if the possibility of ASD morbidity can be determined based on the measured value of each active oxygen scavenging activity, the determination value may be set by using another method.

上記判定要件を導入すると、対象の測定値を、判定要件を具備する区分と、判定要件を具備しない区分の2区分に分割するだけで、ASD罹患可能性を判定することができる。表1に、判定値、判定値による区分を例示する。対象由来のヒドロキシラジカル消去活性が判定値H未満の場合は区分Aに、H以上の場合は区分Bに割り振られ、対象由来のペルオキシラジカル消去活性が判定値PnとPmの間の場合は、区分Aに割り振られる。なお、本明細書において、Pn〜Pm等で示す範囲は、下限値および上限値を含むものとする。 When the above determination requirement is introduced, the possibility of ASD can be determined simply by dividing the target measurement value into two categories, one having the determination requirement and the other not having the determination requirement. Table 1 exemplifies the judgment value and the classification according to the judgment value. If the target-derived hydroxyl radical scavenging activity is less than the judgment value H, it is assigned to category A, if it is H or more, it is assigned to category B, and if the target-derived peroxy radical scavenging activity is between the judgment values Pn and Pm, it is classified into category B. Allocated to A. In this specification, the range indicated by Pn to Pm or the like includes the lower limit value and the upper limit value.

ASD罹患可能性の判定に際し、ヒドロキシラジカル消去活性、スーパーオキシド消去活性、およびアルコキシラジカル消去活性を測定した場合に、ヒドロキシラジカル消去活性は重要度が高いため、ヒドロキシラジカル消去活性が前記判定値未満(第1の判定要件を満たす)であり、かつスーパーオキシド消去活性が前記判定値以上(第2の判定要件を満たす)である場合を「疑い例」と判定し、更にアルコキシラジカル消去活性が前記判定値以上(第3の判定要件を満たす)である場合を「確実例」と判定してもよい。「疑い例」や「確実例」を設けることで、ASD罹患可能性をより確実に判定することができる。 When the hydroxyl radical scavenging activity, the superoxide scavenging activity, and the alkoxy radical scavenging activity are measured in determining the possibility of ASD morbidity, the hydroxyl radical scavenging activity is of high importance, so that the hydroxyl radical scavenging activity is less than the above-mentioned determination value ( The case where the first determination requirement is satisfied) and the superoxide scavenging activity is equal to or higher than the determination value (satisfying the second determination requirement) is determined as a "suspicious example", and the alkoxy radical scavenging activity is further determined. A case where the value is equal to or greater than the value (satisfying the third determination requirement) may be determined as a “certain example”. By providing "suspicious cases" and "certain cases", the possibility of ASD morbidity can be determined more reliably.

(4)スコアによる判定
各活性酸素消去活性を判定値によって区分に割り振り、各区分にスコアを割り付け、スコアの合計でASD罹患可能性を判定することもできる。各前記活性酸素消去活性の前記測定値を、各活性酸素消去活性毎に対応する1つ以上の前記判定値と比較していずれかの区分に振り分け、各活性酸素消去活性のスコアの合計から、ASDへの罹患可能性を判定する。
(4) Judgment by score Each active oxygen scavenging activity can be assigned to each category according to the determination value, a score can be assigned to each category, and the total score can be used to determine the possibility of ASD. The measured value of each active oxygen scavenging activity is compared with one or more of the determination values corresponding to each active oxygen scavenging activity and distributed to any category, and from the total score of each active oxygen scavenging activity, Determine the likelihood of morbidity with ASD.

スコアは、各活性酸素消去活性の各区分毎に設定することができる。スコアを付した1例を表2に示す。X、X、・・・X11で示されるスコアは、それぞれ同一でもよく、異なっていてもよい。表2では、ヒドロキシラジカル消去活性に2個の判定値を導入し、対象の測定値を3つに区分する例を示した。区分数は、各活性酸素毎に同じでも異なっていてもよい。表2では、5種の活性酸素を対象としたが、少なくともヒドロキシラジカル、スーパーオキシドおよびアルコキシラジカルのいずれか2種を用いればよく、5種に限定されるものではない。 The score can be set for each category of each active oxygen scavenging activity. Table 2 shows an example with a score. The scores indicated by X 1 , X 2 , ... X 11 may be the same or different. Table 2 shows an example in which two judgment values are introduced into the hydroxyl radical scavenging activity and the measured values of the target are divided into three. The number of divisions may be the same or different for each active oxygen. In Table 2, five types of active oxygen were targeted, but at least two types of hydroxyl radical, superoxide and alkoxy radical may be used, and the number is not limited to five.

各区分に割り振るスコアは、各活性酸素消去活性値とASDとの関連性の重要度、実施例1に示す感度、特異度、陽性尤度比などを参照し、判定目的と使用状況に応じ決定することができる。たとえば、偽陽性の検出を避けたい場合には高いスコア値を導入し、偽陰性の検出を避けたい場合には低いスコア値を導入することができる。その他、予めASD群と定型発達群の生体材料を用いて活性酸素消去活性を測定し、判定目的や使用状況に応じたASD罹患可能性が判定できるスコアを適宜選択することができる。 The score assigned to each category is determined according to the purpose of determination and the usage situation by referring to the importance of the relationship between each active oxygen scavenging activity value and ASD, the sensitivity, specificity, positive likelihood ratio, etc. shown in Example 1. can do. For example, a high score value can be introduced if false positive detection is desired to be avoided, and a low score value can be introduced if false negative detection is desired to be avoided. In addition, the active oxygen scavenging activity can be measured in advance using biomaterials of the ASD group and the typical development group, and a score capable of determining the possibility of ASD morbidity according to the purpose of determination and the usage situation can be appropriately selected.

使用する判定値は、前記した判定要件に用いる判定値を用いてもよく、異なる判定値を使用してもよい。予め、ASD群と定型発達群の生体材料を用いて各活性酸素消去活性を測定値し、所定の数値を用いて測定値を区分し、感度、特異度、陽性尤度比などを算出し、判定目的や使用状況に応じたASD罹患可能性を判定できる数値を判定値として選択することができる。 As the determination value to be used, the determination value used for the above-mentioned determination requirement may be used, or a different determination value may be used. In advance, each active oxygen scavenging activity is measured using biological materials of the ASD group and the typical development group, the measured values are classified using predetermined numerical values, and the sensitivity, specificity, positive likelihood ratio, etc. are calculated. A numerical value capable of determining the possibility of ASD morbidity according to the determination purpose and usage status can be selected as the determination value.

表2において、対象由来の生体材料の合計スコアの最大値が、例えば13の場合、合計スコアに応じて、合計スコアが8以上をASD罹患陽性などと設定することができる。また、合計スコアに基づいて、5未満を陰性、5以上6未満を偽陰性、6以上8未満を偽陽性、8以上を陽性などと判定してもよい。スコアは、数値に限定されるものではなく、「+」や「−」といった定性的な符号を使用してもよく、「+」や「−」の数に応じて、ASD罹患の可能性を判定してもよい。 In Table 2, when the maximum value of the total score of the biomaterial derived from the subject is, for example, 13, a total score of 8 or more can be set as ASD disease positive or the like according to the total score. Further, based on the total score, it may be determined that less than 5 is negative, 5 or more and less than 6 is false negative, 6 or more and less than 8 is false positive, and 8 or more is positive. The score is not limited to numerical values, and qualitative signs such as "+" and "-" may be used, and the possibility of ASD is determined according to the number of "+" and "-". You may judge.

(5)対象
ASDを判定する対象は、ヒトの他、マウス、ラット、モルモットなどのげっ歯類、サルなどの霊長類であってもよい。これらは非特許文献2に示すようにASDのモデル動物として使用される場合がある。モデル動物構築の指標として、本方法の判定方法を適用することができる。また、対象がヒトの場合、年齢に制限はない。言語能力等が未発達な幼児や小児を対象に含めることができる。
(5) Target The target for determining ASD may be not only humans but also rodents such as mice, rats and guinea pigs, and primates such as monkeys. These may be used as model animals for ASD as shown in Non-Patent Document 2. The determination method of this method can be applied as an index for constructing a model animal. If the subject is a human, there is no age limit. Infants and children with underdeveloped language skills can be included.

本方法で使用できる生体材料としては、末梢血、静脈血、動脈血などの血液、涙、汗、リンパ液、髄液などの体液、毛根、皮膚、口腔粘膜などの細胞組織、尿、唾液、大便などの排泄物がある。血液は、全血でも血清でもよい。 Biological materials that can be used in this method include blood such as peripheral blood, venous blood, and arterial blood, body fluids such as tears, sweat, lymph, and spinal fluid, cell tissues such as hair roots, skin, and oral mucosa, urine, saliva, and stool. There is excrement. The blood may be whole blood or serum.

(6)判定用キット等
本発明のASDの判定用キットは、活性酸素発生剤と、スピントラップ剤とを、対象由来の生体材料に含まれる活性酸素消去活性の測定試薬として含む。活性酸素発生剤としては、過酸化水素、リボフラビン、2,2’−アゾビス[2−アミノジプロパン]ジヒドロクロライド(2,2’-azobis[2-aminodipropane]dihydrochloride(以下AAPHと称す。)、t-butylhydroperoxide(以下t−BuOOHと称す)およびロゼベンガルなどがあり、スピントラップ剤としては、CYPMPO、4−OH−TEMPなどがある。ただし、活性酸素の発生法やスピントラップ剤にはこれらに限定されるものではない。
(6) Judgment kit, etc. The ASD determination kit of the present invention contains an active oxygen generator and a spin trap agent as reagents for measuring active oxygen scavenging activity contained in a biomaterial derived from a target. Examples of the active oxygen generator include hydrogen peroxide, riboflavin, 2,2'-azobis [2-aminodipropane] dihydrochloride (hereinafter referred to as AAPH), and t. There are -butylhydroperoxide (hereinafter referred to as t-BuOOH) and rosebengal, and spin trapping agents include CYPMPO and 4-OH-TEMP, but the method for generating active oxygen and spin trapping agents are limited to these. It's not something.

本発明の判定方法を組み込んだ判定装置を構築することもできる。ESRからの測定値を記憶する記憶装置、測定値と判定値とを比較し、上記判定要件の具備を判断する分析回路、および結果を出力する出力装置を連設させればよい。ESRに記憶装置、分析回路、出力装置などを配設してもよい。 It is also possible to construct a determination device incorporating the determination method of the present invention. A storage device for storing the measured value from the ESR, an analysis circuit for comparing the measured value with the determined value and determining whether or not the determination requirement is satisfied, and an output device for outputting the result may be connected in succession. A storage device, an analysis circuit, an output device, or the like may be arranged in the ESR.

以下、実施例により本発明をさらに具体的に説明する。但し、本発明はこれらに限定されるものではない。なお、活性酸素消去活性は以下の方法で測定し、感度、特異度、陽性尤度比は以下の方法で算定した。 Hereinafter, the present invention will be described in more detail with reference to Examples. However, the present invention is not limited thereto. The active oxygen scavenging activity was measured by the following method, and the sensitivity, specificity, and positive likelihood ratio were calculated by the following method.

(I)活性酸素消去活性の測定方法
各種活性酸素消去活性は、表3に記載する活性酸素発生法、スピントラップ剤を使用し、ESRによるスピントラップ法で測定し、表3に記載する消去活性評価物質の相当量に換算した。
(I) Method for measuring active oxygen scavenging activity Various active oxygen scavenging activities are measured by the active oxygen generation method shown in Table 3 and the spin trap method by ESR using a spin trapping agent, and the scavenging activity shown in Table 3 is used. Converted to a considerable amount of the evaluation substance.

(1)ヒドロキシラジカルの測定
超純水に活性酸素発生剤として過酸化水素およびCYPMPOを各々最終濃度10mMとなるように加えた。これを、ESR(ラジカルリサーチ社製、商品名「RRX−1X」)キャビティー内にセットした測定用セルに導入し、波長300〜400nmの紫外光を5秒間照射してヒドロキシラジカルを発生させた。生成したフリーラジカルを、CYPMPOでスピントラップしてCYPMPO−OHを生成させ、ESR解析用ソフトウエア(ラジカルリサーチ社製、商品名「WIN−RAD」)でCYPMPO−OH信号の波高を測定した。この信号値を(I0)とする。
ついで、サンプルを最終濃度10%となるように、上記過酸化水素およびCYPMPOを各々最終濃度10mM含有する溶液に添加し、上記と同様に操作し、CYPMPO−OH信号の波高を測定した。この信号値を(IS)とし、I0/(IS−1)の値を算出した。
一方、上記サンプルに代えて抗酸化物質としてGSHを用い、上記過酸化水素およびCYPMPOを各々最終濃度10mM含有する溶液に添加し、上記と同様に操作し、CYPMPO−OH信号の波高を測定し、信号値を(IG)とした。複数濃度のGSHで測定し、GSH濃度をX軸、IO/(IG−1)をY軸にプロットして検量線を作成した。この検量線を用い、サンプルのヒドロキシラジカル消去活性であるI0/(IS−1)を、対応するGSHの相当量で算出した。
(1) Measurement of hydroxyl radicals Hydrogen peroxide and CYPMPO were added to ultrapure water as active oxygen generators to a final concentration of 10 mM. This was introduced into a measurement cell set in an ESR (trade name "RRX-1X") cavity manufactured by Radical Research Co., Ltd., and irradiated with ultraviolet light having a wavelength of 300 to 400 nm for 5 seconds to generate hydroxyl radicals. .. The generated free radicals were spin-trapped with CYPMPO to generate CYPMPO-OH, and the wave height of the CYPMPO-OH signal was measured with ESR analysis software (trade name "WIN-RAD" manufactured by Radical Research Co., Ltd.). Let this signal value be (I0).
Then, the sample was added to a solution containing each of the above hydrogen peroxide and CYPMPO at a final concentration of 10 mM so as to have a final concentration of 10%, and the same procedure as above was performed to measure the wave height of the CYPMPO-OH signal. This signal value was defined as (IS), and the value of I0 / (IS-1) was calculated.
On the other hand, GSH was used as an antioxidant in place of the above sample, hydrogen peroxide and CYPMPO were added to a solution containing a final concentration of 10 mM, and the same procedure as above was performed to measure the wave height of the CYPMPO-OH signal. The signal value was (IG). Measurements were made with multiple concentrations of GSH, and the GSH concentration was plotted on the X-axis and IO / (IG-1) on the Y-axis to create a calibration curve. Using this calibration curve, I0 / (IS-1), which is the hydroxyl radical scavenging activity of the sample, was calculated with an equivalent amount of the corresponding GSH.

(2)スーパーオキシドの測定
過酸化水素に代えて最終濃度20μMのリボフラビンを加え、および紫外光照射に代えて波長500〜600nmの可視光を60秒照射した以外は(1)のヒドロキシラジカルの測定と同様に操作し、信号値(IS)を測定し、およびI0/(IS−1)を算出した。次いで、GSHに代えてスーパーオキシド不均化酵素(SOD)を使用した以外は(1)のヒドロキシラジカルの測定と同様に操作して検量線を作成し、サンプルのスーパーオキシド消去活性であるI0/(IS−1)を、対応するSODの相当量で算出した。
(2) Measurement of superoxide Measurement of hydroxyl radical in (1) except that riboflavin having a final concentration of 20 μM was added instead of hydrogen peroxide, and visible light having a wavelength of 500 to 600 nm was irradiated for 60 seconds instead of ultraviolet light irradiation. The signal value (IS) was measured and I0 / (IS-1) was calculated. Next, a calibration curve was prepared in the same manner as in the measurement of hydroxyl radical in (1) except that superoxide dismutase (SOD) was used instead of GSH, and I0 /, which is the superoxide scavenging activity of the sample. (IS-1) was calculated with a corresponding amount of SOD.

(3)アルコキシラジカルの測定
過酸化水素に代えて、最終濃度1mMのAAPHを加えた以外は(1)のヒドロキシラジカルの測定と同様に操作し、信号値(IS)を測定し、およびI0/(IS−1)を算出した。次いで、GSHに代えてトロロクスを使用した以外は(1)のヒドロキシラジカルの測定と同様に操作して検量線を作成し、サンプルのアルコキシラジカル消去活性であるI0/(IS−1)を、対応するトロロクスの相当量で算出した。
(3) Measurement of alkoxy radicals The same procedure as the measurement of hydroxyl radicals in (1) was performed except that AAPH having a final concentration of 1 mM was added instead of hydrogen peroxide, and the signal value (IS) was measured, and I0 / (IS-1) was calculated. Next, a calibration curve was prepared by operating in the same manner as in the measurement of hydroxyl radicals in (1) except that trolox was used instead of GSH, and I0 / (IS-1), which is the alkoxy radical scavenging activity of the sample, was dealt with. It was calculated by the equivalent amount of hydroxylox.

(4)ペルオキシラジカルの測定
過酸化水素に代えて、最終濃度10mMのt−BuOOHを加えた以外は(1)のヒドロキシラジカルの測定と同様に操作し、信号値(IS)を測定し、およびI0/(IS−1)を算出した。次いで、GSHに代えてα−リポ酸を使用した以外は(1)のヒドロキシラジカルの測定と同様に操作して検量線を作成し、サンプルのペルオキシラジカル消去活性であるI0/(IS−1)を、対応するリポ酸の相当量で算出した。
(4) Measurement of peroxy radical The signal value (IS) was measured and the signal value (IS) was measured by operating in the same manner as the measurement of hydroxyl radical in (1) except that t-BuOOH having a final concentration of 10 mM was added instead of hydrogen peroxide. I0 / (IS-1) was calculated. Next, a calibration curve was prepared by operating in the same manner as in the measurement of hydroxyl radical in (1) except that α-lipoic acid was used instead of GSH, and I0 / (IS-1), which is the peroxy radical scavenging activity of the sample. Was calculated with the equivalent amount of the corresponding lipoic acid.

(5)一重項酸素の測定
過酸化水素最終濃度200μMのロゼベンガルを加え、および紫外光に代えて波長500〜600nmの可視光を60秒照射し、CYPMPOに代えて4−OH−TEMPを用いた以外は(1)のヒドロキシラジカルの測定と同様に操作し、信号値(IS)を測定し、およびI0/(IS−1)を算出した。次いで、(1)のヒドロキシラジカルの測定と同様に操作して検量線を作成し、サンプルの一重項酸素消去活性であるI0/(IS−1)を、対応するGSHの相当量で算出した。
(5) Measurement of singlet oxygen Rosebengal with a final concentration of hydrogen peroxide of 200 μM was added, and visible light with a wavelength of 500 to 600 nm was irradiated for 60 seconds instead of ultraviolet light, and 4-OH-TEMP was used instead of CYPMPO. Except for the above, the procedure was the same as for the measurement of hydroxyl radical in (1), the signal value (IS) was measured, and I0 / (IS-1) was calculated. Next, a calibration curve was prepared by operating in the same manner as in the measurement of hydroxyl radical in (1), and I0 / (IS-1), which is the singlet oxygen scavenging activity of the sample, was calculated with the corresponding amount of GSH.

(II)判定値の算出方法
定型発達群とASD群を所定の判定値で区分すると、表4に示すようにTN(真陰性)、TP(真陽性)、FN(偽陰性)およびFP(偽陽性)の4区分に分画される。TNは、ヒドロキシラジカル消去活性が、カットオフ値を超える定型発達群であり、またスーパーオキシドおよびアルコキシラジカル消去活性においてカットオフ値を下回る定型発達群であり、定型発達群が正常であると判定される区分である。また、TPは、ヒドロキシラジカル消去活性においてカットオフ値を下回るASD群であり、またスーパーオキシドおよびアルコキシラジカル消去活性においてカットオフ値を超えるASD群であり、ASD群がASDであると判定される区分である。一方、FNはASDでありながら正常と判定される区分、同様にFPは正常であるにも関わらずASDと判定される区分である。
(II) Method of calculating judgment values When the neurotypical development group and the ASD group are classified by predetermined judgment values, TN (true negative), TP (true positive), FN (false negative) and FP (false negative) are shown in Table 4. It is divided into 4 categories (positive). TN is a neurotypical development group in which the hydroxyl radical scavenging activity exceeds the cutoff value, and is a neurotypical development group in which the superoxide and alkoxy radical scavenging activities are lower than the cutoff value, and the neurotypical development group is determined to be normal. It is a division. Further, TP is an ASD group having a hydroxyl radical scavenging activity lower than the cutoff value, and an ASD group having a superoxide and alkoxy radical scavenging activity exceeding the cutoff value, and the ASD group is determined to be ASD. Is. On the other hand, FN is a category that is determined to be normal even though it is ASD, and FP is a category that is determined to be ASD even though it is normal.

感度(SN)とは、ASD群が陽性になる確率を意味し、SN=TP/(TP+FN)で算出される。また、特異度(SP)とは、定型発達群が陰性になる確率であり、SP=TN/(FP+TN)で算出される。陽性尤度比(LR+)とは、真陽性(TP)の割合と偽陽性(FP)の割合の比であり、LR+=(TP/(TP+FN))/(FP/(FP+TN))=SN/(1−SP)で算出される。 Sensitivity (SN) means the probability that the ASD group will be positive, and is calculated by SN = TP / (TP + FN). The specificity (SP) is the probability that the typical development group becomes negative, and is calculated by SP = TN / (FP + TN). The positive likelihood ratio (LR +) is the ratio of the ratio of true positives (TP) to the ratio of false positives (FP), and LR + = (TP / (TP + FN)) / (FP / (FP + TN)) = SN / It is calculated by (1-SP).

定型発達群とASD群において有意差が存在する場合、カットオフ値を変数として、X軸に(1−SP)、Y軸に感度(SN)をプロットして受信者動作特性曲線(ROC曲線)を作成し、(SN/(1−SP))が最大値となるYouden Indexをカットオフ値として特定した。なお、前記ROC曲線の曲線下面積をAUC(area under curve)と称する。所定の検査方法において、定型発達群とASD群の間で検査結果に差が検出される場合、AUCは0.5〜1.0となる。AUCが0.9〜1.0の場合、前記所定の検査方法は高い正確性を有すると考えられ、0.7〜0.9の場合、その正確性は中等度と考えられている。 When there is a significant difference between the typical development group and the ASD group, the receiver operating characteristic curve (ROC curve) is plotted by plotting (1-SP) on the X-axis and sensitivity (SN) on the Y-axis with the cutoff value as a variable. Was created, and the Youden Index with the maximum value of (SN / (1-SP)) was specified as the cutoff value. The area under the curve of the ROC curve is referred to as AUC (area under curve). If a difference is detected in the test results between the neurotypical development group and the ASD group in a predetermined test method, the AUC will be 0.5 to 1.0. When the AUC is 0.9 to 1.0, the predetermined inspection method is considered to have high accuracy, and when 0.7 to 0.9, the accuracy is considered to be moderate.

一方、定型発達群とASD群において有意差がない場合は、両群の95%信頼区間を元に同等とみなす区間を設定し、この区間を用いてある対象の活性酸素消去活性が同等であるか否かを判定した。 On the other hand, if there is no significant difference between the neurotypical development group and the ASD group, a section to be regarded as equivalent is set based on the 95% confidence interval of both groups, and the active oxygen scavenging activity of a subject using this section is equivalent. It was judged whether or not.

(III)事後確率の算出
事前確率とは、条件付確率の一種で、ある変数について知られていることを確率として表現したものであり、当該方法を用いる前の段階でASDと考えられる確率である。また、事後確率とは、事前確率の判断の後に当該方法を用い陽性と判断された場合ASDを有する確率であり、例えば、当該方法を用い陽性と判断された場合にASDを有する確率である。
(III) Calculation of posterior probabilities Prior probabilities are a type of conditional probabilities that express what is known about a variable as probabilities, and are probabilities that are considered to be ASD before the method is used. is there. The posterior probability is a probability of having ASD when it is determined to be positive by using the method after determining the prior probability, and is, for example, a probability of having ASD when it is determined to be positive by using the method.

また、事前確率より事前オッズを計算し、事前オッズに陽性尤度関数を掛けることで事後オッズが得られ、事後オッズから事後確率を得ることができる。事前オッズは「事前確率/(1−事前確率)」、事後オッズは「事後確率/(1−事後確率)」で表される。陽性尤度比とは検査が陽性だった場合の尤度の比であり、大きいほど疾病確定判定方法にすぐれることを意味する。 In addition, the posterior odds can be obtained by calculating the prior odds from the prior probability and multiplying the prior odds by the positive likelihood function, and the posterior probability can be obtained from the posterior odds. Prior odds are represented by "prior probabilities / (1-posterior probabilities)", and posterior odds are represented by "posterior probabilities / (1-posterior probabilities)". The positive likelihood ratio is the ratio of the likelihood when the test is positive, and the larger the ratio, the better the disease confirmation method.

なお、事後オッズ算出の際の陽性尤度比は、測定対象の反応機構が独立している場合、各機構に基づく陽性尤度比の積で算出することができる。例えば、活性酸素種の消去機構がそれぞれ独立している場合、A活性酸素消去能に基づく陽性尤度比AとB活性酸素消去能に基づく陽性尤度比Bを求め、事後オッズ=陽性尤度比A×陽性尤度比B×事前オッズとして算出することができる。 When the reaction mechanism to be measured is independent, the positive likelihood ratio at the time of calculating the ex-post odds can be calculated by the product of the positive likelihood ratios based on each mechanism. For example, when the scavenging mechanisms of active oxygen species are independent, the positive likelihood ratio A based on the active oxygen scavenging ability A and the positive likelihood ratio B based on the active oxygen scavenging ability are obtained, and the post-odds = positive likelihood. It can be calculated as ratio A × positive likelihood ratio B × pre-odds.

(実施例1)
児童精神医学専門医の診察を受けた5歳以下のASD(n=22〜23)および定型発達児(n=33〜34)の末梢血液を採取した。生体成分に含まれるヒドロキシラジカル消去活性、スーパーオキシド消去活性、アルコキシラジカル消去活性、ペルオキシラジカル消去活性および一重項酸素消去活性を上記したESRによるスピントラップ法により測定した。
(Example 1)
Peripheral blood was collected from ASD (n = 22-23) and neurotypical infants (n = 33-34) under the age of 5 who were examined by a child and adolescent psychiatrist. Hydroxyl radical scavenging activity, superoxide scavenging activity, alkoxy radical scavenging activity, peroxy radical scavenging activity and singlet oxygen scavenging activity contained in biological components were measured by the spin trap method by ESR described above.

各種活性酸素消去活性のt検定による群間比較の結果を図1に示す。図1に示すように、ASD群は定型発達群に比べ、ヒドロキシラジカル消去活性が有意に低下した。一方、スーパーオキシドおよびアルコキシラジカル消去活性は有意に上昇していた。ペルオキシラジカルおよび一重項酸素に対する消去活性は両群で差が認められなかった。 The results of comparison between groups by t-test of various active oxygen scavenging activities are shown in FIG. As shown in FIG. 1, the hydroxyl radical scavenging activity of the ASD group was significantly lower than that of the typical development group. On the other hand, the superoxide and alkoxy radical scavenging activities were significantly increased. There was no difference in scavenging activity for peroxy radicals and singlet oxygen between the two groups.

ヒドロキシラジカル、スーパーオキシド、およびアルコキシラジカルの消去活性は、ASD群と定型発達群との間に統計学的有意差が検出され、判定値としてカットオフ値を用いた。統計学的有意差を示さない活性酸素種、すなわちペルオキシラジカル、一重項酸素については、判定要件として95%信頼区間をもとに設定した同等とみなす区間の間にあるものとし、判定値は、前記区間の上限値と下限値とした。表5に、判定値、判定要件、感度、特異度、陽性尤度比、AUC、各群の95%信頼区間を示す。 Statistically significant differences were detected between the ASD group and the neurotypical development group in the scavenging activity of hydroxyl radicals, superoxide, and alkoxy radicals, and the cutoff value was used as the determination value. Reactive oxygen species that do not show a statistically significant difference, that is, peroxy radicals and singlet oxygen, are assumed to be between the intervals considered to be equivalent set based on the 95% confidence interval as the judgment requirement, and the judgment value is The upper and lower limits of the section were set. Table 5 shows the determination values, determination requirements, sensitivity, specificity, positive likelihood ratio, AUC, and 95% confidence intervals for each group.

ヒドロキシラジカル消去活性に関し、ASD群を5.3mMGSH相当未満とした場合
感度(SN)=TP/(TP+FN)=13/22=0.59
特異度(SP)=TN/(TN+FP)=26/33=0.79
陽性尤度比=SN/(1−SP)=(13/22)/(7/33)=2.79
AUC=0.85
Regarding hydroxyl radical scavenging activity, when the ASD group is less than 5.3 mM GSH equivalent Sensitivity (SN) = TP / (TP + FN) = 13/22 = 0.59
Specificity (SP) = TN / (TN + FP) = 26/33 = 0.79
Positive likelihood ratio = SN / (1-SP) = (13/22) / (7/33) = 2.79
AUC = 0.85

スーパーオキシド消去活性に関し、ASD群を9.35U/mlSOD相当以上とした場合
感度(SN)=TP/(TP+FN)=16/23=0.70
特異度(SP)=TN/(TN+FP)=32/33=0.97
陽性尤度比=SN/(1−SP)=(16/23)/(1/33)=23.0
AUC=0.87
Regarding superoxide scavenging activity, when the ASD group is equivalent to 9.35 U / ml SOD or more, sensitivity (SN) = TP / (TP + FN) = 16/23 = 0.70
Specificity (SP) = TN / (TN + FP) = 32/33 = 0.97
Positive likelihood ratio = SN / (1-SP) = (16/23) / (1/33) = 23.0
AUC = 0.87

アルコキシラジカル消去活性に関し、ASD群を1.95mMトロロクス相当以上とした場合
感度(SN)=TP/(TP+FN)=15/23=0.65
特異度(SP)=TN/(TN+FP)=25/34=0.74
陽性尤度比=SN/(1−SP)=(15/23)/(9/34)=2.46
AUC=0.86
Regarding the alkoxy radical scavenging activity, when the ASD group is equivalent to 1.95 mM trolox or more, sensitivity (SN) = TP / (TP + FN) = 15/23 = 0.65
Specificity (SP) = TN / (TN + FP) = 25/34 = 0.74
Positive likelihood ratio = SN / (1-SP) = (15/23) / (9/34) = 2.46
AUC = 0.86

ペルオキシラジカル消去活性に関し、ASD群を0.24〜1.08mMα−リポ酸相当とした場合
感度(SN)=TP/(TP+FN)=18/23=0.78
特異度(SP)=TN/(TN+FP)=23/33=0.70
陽性尤度比=SN/(1−SP)=(18/23)/(10/33)=2.58
Regarding peroxy radical scavenging activity, when the ASD group is equivalent to 0.24 to 1.08 mM α-lipoic acid, sensitivity (SN) = TP / (TP + FN) = 18/23 = 0.78
Specificity (SP) = TN / (TN + FP) = 23/33 = 0.70
Positive likelihood ratio = SN / (1-SP) = (18/23) / (10/33) = 2.58

一重項酸素消去活性に関し、ASD群を13〜21μMGSH相当とした場合
感度(SN)=TP/(TP+FN)=9/23=0.39
特異度(SP)=TN/(TN+FP)=27/33=0.81
陽性尤度比=SN/(1−SP)=(9/23)/(6/33)=2.15
Regarding singlet oxygen scavenging activity, when the ASD group is equivalent to 13 to 21 μMGSH Sensitivity (SN) = TP / (TP + FN) = 9/23 = 0.39
Specificity (SP) = TN / (TN + FP) = 27/33 = 0.81
Positive likelihood ratio = SN / (1-SP) = (9/23) / (6/33) = 2.15

図2に、ヒドロキシルラジカル消去活性測定、アルコキシラジカル消去活性測定、およびスーパーオキシド消去活性測定に基づく事前確率と事後確率との関係を示し、それぞれ曲線I、II、IIIで示した。更に、ヒドロキシルラジカル消去活性測定とアルコキシラジカル消去活性測定に基づく事前確率と事後確率との関係を曲線I+IIに、ヒドロキシルラジカル消去活性測定、アルコキシラジカル消去活性測定、およびスーパーオキシド消去活性測定に基づく事前確率と事後確率との関係を曲線I+II+IIIに示す。 FIG. 2 shows the relationship between the prior probability and the posterior probability based on the hydroxyl radical scavenging activity measurement, the alkoxy radical scavenging activity measurement, and the superoxide scavenging activity measurement, and is shown by curves I, II, and III, respectively. Furthermore, the relationship between the prior probability and posterior probability based on the hydroxyl radical scavenging activity measurement and the alkoxy radical scavenging activity measurement is shown in curve I + II, and the prior probability based on the hydroxyl radical scavenging activity measurement, the alkoxy radical scavenging activity measurement, and the superoxide scavenging activity measurement. The relationship between radicals and posterior probabilities is shown in curves I + II + III.

ASDにおける各活性酸素種の消去機構はそれぞれ独立しているため、ヒドロキシルラジカル消去活性に基づく陽性尤度度、アルコキシラジカル消去活性に基づく陽性尤度比から、ヒドロキシルラジカル消去活性における陽性尤度比×アルコキシラジカル消去活性における陽性尤度比×事前オッズ=事後オッズと算出することができる。表5を参照すれば、曲線I+IIの事後オッズは、2.79×2.46×事前オッズ=6.86×事前オッズと算出される。同様にヒドロキシルラジカル消去活性、スーパーオキシド消去活性、およびアルコキシラジカル消去活性の3種類に基づいて評価した場合、曲線I+II+IIIの事後オッズは、2.79×23.0×2.46=157.9×事前オッズと算出される。血清のヒドロキシルラジカル消去活性、アルコキシラジカル消去活性およびスーパーオキシド消去活性を測定し、いずれも検査陽性であった場合には、図2に示すように事前確率が50%のときの事後確率は99%であり、ASDの判定に際し非常に有用な方法であることが判明した。 Since the scavenging mechanism of each reactive oxygen species in ASD is independent, the positive likelihood ratio based on the hydroxyl radical scavenging activity and the positive likelihood ratio based on the alkoxy radical scavenging activity are divided into the positive likelihood ratio in the hydroxyl radical scavenging activity × It can be calculated as positive likelihood ratio in alkoxy radical scavenging activity × pre-odds = post-odds. With reference to Table 5, the posterior odds of the curve I + II are calculated as 2.79 × 2.46 × pre-odds = 6.86 × pre-odds. Similarly, when evaluated based on three types of hydroxyl radical scavenging activity, superoxide scavenging activity, and alkoxy radical scavenging activity, the posterior odds of curve I + II + III are 2.79 × 23.0 × 2.46 = 157.9 ×. Calculated as pre-odds. When the hydroxyl radical scavenging activity, the alkoxy radical scavenging activity and the superoxide scavenging activity of the serum are measured and all of them are positive in the test, the posterior probability is 99% when the prior probability is 50% as shown in FIG. It turned out to be a very useful method in determining ASD.

図1を加味すれば、ペルオキシラジカルおよび一重項酸素が基準範囲内にある場合には、特異度を100%とすることができる。 Taking FIG. 1 into consideration, the specificity can be set to 100% when the peroxy radical and singlet oxygen are within the reference range.

(実施例2)
実施例1のASD(n=22〜23)および定型発達児(n=33〜34)の末梢血液について、実施例1の判定値を使用して各活性酸素消去活性値を区分し、各区分に表6に記載のスコアを付した。
(Example 2)
For the peripheral blood of ASD (n = 22 to 23) and typical developing infants (n = 33 to 34) of Example 1, each active oxygen scavenging activity value was classified using the judgment value of Example 1, and each classification was performed. The scores shown in Table 6 are attached to.

対象由来の生体材料のヒドロキシラジカル消去活性が5mMGSH相当、スーパーオキシド消去活性が10U/mlSOD相当、アルコキシラジカル消去活性が2mMトロロクス相当、ペルオキシラジカル消去活性が0.7mMα−リポ酸相当、一重項酸素消去活性が15μMGSH相当の場合、スコアの合計は11となる。スコア値6.5以上を陽性とした場合、この対象は感度65%(95%信頼区間42〜83%)、特異度97%(95%信頼区間84〜99%)、陽性尤度比22.17の状況において陽性とされ、すなわちASDに罹患している可能性が高いと判断することができる。 Hydroxyl radical scavenging activity of subject-derived biomaterial is equivalent to 5 mM GSH, superoxide scavenging activity is equivalent to 10 U / ml SOD, alkoxy radical scavenging activity is equivalent to 2 mM trolox, peroxy radical scavenging activity is equivalent to 0.7 mM α-lipoic acid, singlet oxygen scavenging. If the activity is equivalent to 15 μM GSH, the total score is 11. When a score of 6.5 or higher is positive, this subject has a sensitivity of 65% (95% confidence interval 42-83%), a specificity of 97% (95% confidence interval 84-99%), and a positive likelihood ratio of 22. It can be determined that it is positive in 17 situations, that is, it is highly likely that it has ASD.

Claims (7)

対象由来の生体材料のヒドロキシラジカル消去活性、スーパーオキシド消去活性およびアルコキシラジカル消去活性からなる群より選択される少なくとも2以上の活性酸素消去活性の測定値を、前記各活性酸素消去活性に対応する判定値と比較し、当該比較結果に基づき、前記対象が自閉症スペクトラム障害に罹患している可能性を求める判定工程を含み、
前記判定工程では、前記比較結果が、以下に列記する判定要件、
前記ヒドロキシラジカル消去活性の測定値を含む場合、当該測定値が前記ヒドロキシラジカル消去活性の判定値未満であるという第1の判定要件、
前記スーパーオキシド消去活性の測定値を含む場合、当該測定値が前記スーパーオキシド消去活性の判定値以上であるという第2の判定要件、および
前記アルコキシラジカル消去活性の測定値を含む場合、当該測定値が前記アルコキシラジカル消去活性の判定値以上であるという第3の判定要件、を満たすか否かを示すものであり、
前記第1の判定要件、第2の判定要件および第3の判定要件のいずれか2つ以上満たす場合に前記対象は自閉症スペクトラム障害に罹患している可能性ありと判定するものであり、
前記判定値は、定型発達群および自閉症スペクトラム障害群での前記活性酸素消去活性の測定値に基づき予め決定され、前記定型発達群と前記自閉症スペクトラム障害群とで統計的有意差がある場合はカットオフ値とし、
前記自閉症スペクトラム障害群と前記定型発達群との間に統計的有意差が無い場合は所定の信頼区間を設定し同等性検定を行い、優越性が無く同等性を示す上限値と下限値をそれぞれ判定値とするものである、自閉症スペクトラム障害の判定方法。
The measurement value of at least two or more active oxygen scavenging activities selected from the group consisting of hydroxyl radical scavenging activity, superoxide scavenging activity and alkoxy radical scavenging activity of the biological material derived from the subject is determined to correspond to each of the active oxygen scavenging activities. Including a determination step of comparing with the value and determining the possibility that the subject has autism spectrum disorder based on the comparison result.
In the determination step, the comparison result is the determination requirement listed below.
When the measured value of the hydroxyl radical scavenging activity is included, the first determination requirement that the measured value is less than the determination value of the hydroxyl radical scavenging activity,
When the measurement value of the superoxide scavenging activity is included, the second determination requirement that the measurement value is equal to or higher than the determination value of the superoxide scavenging activity, and when the measurement value of the alkoxy radical scavenging activity is included, the measurement value is included. Indicates whether or not satisfies the third determination requirement that is equal to or greater than the determination value of the alkoxy radical scavenging activity.
When any two or more of the first determination requirement, the second determination requirement, and the third determination requirement are satisfied, it is determined that the subject may be suffering from autism spectrum disorder .
The determination value is determined in advance based on the measured values of the active oxygen scavenging activity in the typical development group and the autism spectrum disorder group, and there is a statistically significant difference between the typical development group and the autism spectrum disorder group. If there is, use the cutoff value
If there is no statistically significant difference between the autism spectrum disorder group and the neurotypical development group, a predetermined confidence interval is set and an equivalence test is performed, and an upper limit value and a lower limit value indicating equivalence without superiority are performed. A method for determining autism spectrum disorder, each of which has a determination value of .
前記活性酸素消去活性は、ペルオキシラジカル消去活性および/または一重項酸素消去活性をさらに含み、
前記判定工程は、更に、
前記ペルオキシラジカル消去活性の測定値を含む場合、当該測定値が前記ペルオキシラジカル消去活性の2つの判定値の間にあるという第4の判定要件、および/または、
前記一重項酸素消去活性の測定値を含む場合、当該測定値が前記一重項酸素消去活性の2つの判定値の間にあるという第5の判定要件を含み、
前記第4の判定要件または前記第5の判定要件を満たす場合に前記対象は自閉症スペクトラム障害に罹患している可能性がより高いと判定する、請求項1に記載の判定方法。
The active oxygen scavenging activity further includes a peroxy radical scavenging activity and / or a singlet oxygen scavenging activity.
The determination step further
When the measured value of the peroxy radical scavenging activity is included, the fourth determination requirement that the measured value is between the two determination values of the peroxy radical scavenging activity, and / or
When the measurement value of the singlet oxygen scavenging activity is included, the fifth determination requirement that the measurement value is between the two determination values of the singlet oxygen scavenging activity is included.
The determination method according to claim 1, wherein when the fourth determination requirement or the fifth determination requirement is satisfied, it is determined that the subject is more likely to have an autism spectrum disorder.
前記判定工程は、前記各活性酸素消去活性の前記測定値を、対応する1つ以上の前記判定値と比較し、当該比較結果に基づいて前記各活性酸素消去活性にスコアを割り付け、自閉症スペクトラム障害への罹患可能性を前記スコアの合計値として求める、請求項1または2に記載の判定方法。 In the determination step, the measured value of each active oxygen scavenging activity is compared with one or more corresponding determination values, and a score is assigned to each active oxygen scavenging activity based on the comparison result, and autism The determination method according to claim 1 or 2, wherein the possibility of suffering from a spectrum disorder is determined as the total value of the scores. 前記各活性酸素消去活性は、電子スピン共鳴によるスピントラップ法で測定されることを特徴とする、請求項1〜3のいずれか1項に記載の判定方法。 The determination method according to any one of claims 1 to 3, wherein each active oxygen scavenging activity is measured by a spin trap method using electron spin resonance. 過酸化水素、リボフラビン、および2,2’−アゾビス[2−アミノジプロパン]ジヒドロクロライドからなる群から選択される2以上の活性酸素発生剤と、スピントラップ剤とを、前記対象由来の生体材料に含まれる前記活性酸素消去活性の測定試薬として含む、請求項1〜4のいずれか1項に記載の判定方法を実施するための、自閉症スペクトラム障害の判定用キット Two or more active oxygen generators selected from the group consisting of hydrogen peroxide, riboflavin, and 2,2'-azobis [2-aminodipropane] dihydrochloride, and a spin trap agent are used as biomaterials derived from the subject. A kit for determining autism spectrum disorder for carrying out the determination method according to any one of claims 1 to 4, which is contained as a reagent for measuring the active oxygen scavenging activity contained in the above . 活性酸素発生剤としてt-butylhydroperoxideを前記対象由来の生体材料に含まれる前記活性酸素消去活性の測定試薬としてさらに含み、および/または、活性酸素発生剤としてローズベンガルと、スピントラップ剤とを、前記対象由来の生体材料に含まれる前記活性酸素消去活性の測定試薬としてさらに含む、請求項2に記載の判定方法を実施するための、請求項5に記載された自閉症スペクトラム障害の判定用キット。 Further containing t-butyl hydropero x ide as an active oxygen generator as a measurement reagent for the active oxygen scavenging activity contained in the biological material derived from the subject, and / or rose bengal as an active oxygen generator and a spin trap agent. The determination of autism spectrum disorder according to claim 5 for carrying out the determination method according to claim 2, which is further contained as a measurement reagent for the active oxygen scavenging activity contained in the biological material derived from the subject. Kit for. 対象由来の生体材料のヒドロキシラジカル消去活性、スーパーオキシド消去活性およびアルコキシラジカル消去活性からなる群より選択される少なくとも2以上の活性酸素消去活性、およびペルオキシラジカル消去活性および/または一重項酸素消去活性の活性酸素消去活性の測定値を、前記各活性酸素消去活性に対応する判定値と比較し、当該比較結果に基づき、前記対象が自閉症スペクトラム障害に罹患している可能性を求めるための測定データ処理工程を含み、
前記測定データ処理工程では、前記比較結果が、以下に列記する条件、
前記ヒドロキシラジカル消去活性の測定値を含む場合、当該測定値が前記ヒドロキシラジカル消去活性の判定値未満であるという第1の条件、
前記スーパーオキシド消去活性の測定値を含む場合、当該測定値が前記スーパーオキシド消去活性の判定値以上であるという第2の条件、
前記アルコキシラジカル消去活性の測定値を含む場合、当該測定値が前記アルコキシラジカル消去活性の判定値以上であるという第3の条件、
前記ペルオキシラジカル消去活性の測定値を含む場合、当該測定値が前記ペルオキシラジカル消去活性の2つの判定値の間にあるという第4の条件、および/または、
前記一重項酸素消去活性の測定値を含む場合、当該測定値が前記一重項酸素消去活性の2つの判定値の間にあるという第5の条件を含み、
前記第1の条件、第2の条件および第3の条件のいずれか2つ以上満たし、且つ、前記第4の条件または前記第5の条件を満たす場合に前記対象は自閉症スペクトラム障害に罹患している可能性が高いと判定するための測定データ取得方法であって、
前記判定値は、定型発達群および自閉症スペクトラム障害群での前記活性酸素消去活性の測定値に基づき予め決定され、前記定型発達群と前記自閉症スペクトラム障害群とで統計的有意差がある場合はカットオフ値とし、
前記自閉症スペクトラム障害群と前記定型発達群との間に統計的有意差が無い場合は所定の信頼区間を設定し同等性検定を行い、優越性が無く同等性を示す上限値と下限値をそれぞれ判定値とするものである、測定データ取得方法
At least two or more active oxygen scavenging activities selected from the group consisting of hydroxyl radical scavenging activity, superoxide scavenging activity and alkoxy radical scavenging activity, and peroxy radical scavenging activity and / or singlet oxygen scavenging activity of the biological material derived from the subject. Measurement for comparing the measured value of the active oxygen scavenging activity with the determination value corresponding to each of the active oxygen scavenging activities, and determining the possibility that the subject suffers from autism spectrum disorder based on the comparison result. Including data processing process
In the measurement data processing step, the comparison results are based on the conditions listed below.
When the measured value of the hydroxyl radical scavenging activity is included, the first condition that the measured value is less than the determination value of the hydroxyl radical scavenging activity,
When the measured value of the superoxide scavenging activity is included, the second condition that the measured value is equal to or higher than the determination value of the superoxide scavenging activity.
When the measured value of the alkoxy radical scavenging activity is included, the third condition that the measured value is equal to or higher than the determination value of the alkoxy radical scavenging activity.
When the measured value of the peroxy radical scavenging activity is included, the fourth condition that the measured value is between the two determination values of the peroxy radical scavenging activity, and / or
When the measured value of the singlet oxygen scavenging activity is included, the fifth condition that the measured value is between the two determination values of the singlet oxygen scavenging activity is included.
If any two or more of the first condition, the second condition, and the third condition are satisfied, and the fourth condition or the fifth condition is satisfied, the subject suffers from autism spectrum disorder. a measurement data acquisition method for the possibility that it is determined that high
The determination value is determined in advance based on the measured values of the active oxygen scavenging activity in the typical development group and the autism spectrum disorder group, and there is a statistically significant difference between the typical development group and the autism spectrum disorder group. If there is, use the cutoff value
If there is no statistically significant difference between the autism spectrum disorder group and the typical development group, a predetermined confidence interval is set and an equivalence test is performed, and an upper limit value and a lower limit value indicating equivalence without superiority are performed. Is a measurement data acquisition method, each of which has a determination value of .
JP2016170479A 2016-09-01 2016-09-01 Autism spectrum disorder determination method, autism spectrum disorder determination kit and measurement data acquisition method Active JP6830578B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2016170479A JP6830578B2 (en) 2016-09-01 2016-09-01 Autism spectrum disorder determination method, autism spectrum disorder determination kit and measurement data acquisition method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2016170479A JP6830578B2 (en) 2016-09-01 2016-09-01 Autism spectrum disorder determination method, autism spectrum disorder determination kit and measurement data acquisition method

Publications (3)

Publication Number Publication Date
JP2018033393A JP2018033393A (en) 2018-03-08
JP2018033393A5 JP2018033393A5 (en) 2019-03-07
JP6830578B2 true JP6830578B2 (en) 2021-02-17

Family

ID=61564705

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016170479A Active JP6830578B2 (en) 2016-09-01 2016-09-01 Autism spectrum disorder determination method, autism spectrum disorder determination kit and measurement data acquisition method

Country Status (1)

Country Link
JP (1) JP6830578B2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024005001A1 (en) * 2022-06-30 2024-01-04 株式会社バイオラジカル研究所 Method for testing mild cognitive impairment, test reagent for mild cognitive impairment, and method for screening therapeutic candidate substances for mild cognitive impairment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2779060B2 (en) * 1990-10-31 1998-07-23 日本電子株式会社 Glutathione determination method
CA2723118C (en) * 2008-05-02 2016-05-17 University Of Tsukuba Polymerized cyclic nitroxide radical compound and use thereof
JP2010067050A (en) * 2008-09-11 2010-03-25 Fancl Corp Device and method for estimating singlet oxygen quenching activity
CN105911275B (en) * 2009-08-14 2018-06-29 加利福尼亚大学董事会 Diagnose the kit of self-closing disease
US8518659B2 (en) * 2009-10-14 2013-08-27 Natonal University Corporation Hamamatsu University School of Medicine Method for determination of degree of risk of onset of high-functioning autism

Also Published As

Publication number Publication date
JP2018033393A (en) 2018-03-08

Similar Documents

Publication Publication Date Title
Björkman et al. Validity of the revised Ekblom Bak cycle ergometer test in adults
Abdullah et al. Heavy metal in children’s tooth enamel: related to autism and disruptive behaviors?
Milojev et al. Normative personality trait development in adulthood: A 6-year cohort-sequential growth model.
Stephan et al. Feeling older and risk of hospitalization: Evidence from three longitudinal cohorts.
Etzel et al. Prenatal urinary triclosan concentrations and child neurobehavior
Phillips et al. Effect of influenza vaccination on oxidative stress products in breath
Rolle-McFarland et al. The association of bone, fingernail and blood manganese with cognitive and olfactory function in Chinese workers
JPWO2011152012A1 (en) Examination method of disease severity
US20260062734A1 (en) Test method for mild cognitive impairment, test reagent for mild cognitive impairment, and method for screening therapeutic candidate substances for mild cognitive impairment
Edwards et al. A Bayesian approach to estimating the population prevalence of mood and anxiety disorders using multiple measures
Jiménez-Texcalpaa et al. Implementation of the Pediatric Index of Mortality 3 and the pediatric Sequential Organ Failure Assessment in an intensive care unit in Mexico
JP6830578B2 (en) Autism spectrum disorder determination method, autism spectrum disorder determination kit and measurement data acquisition method
Salzillo et al. Sudden cardiac death in the young: Single-center study of Bari autopsy cases
Debowska et al. The PCL–R family of psychopathy measures: Dimensionality and predictive utility of the PCL–R, PCL: SV, PCL: YV, SRP–III, and SRP–SF
Peniche-Palma et al. Levels of myeloperoxidase and Metalloproteinase‐9 in gingival crevicular fluid from diabetic subjects with and without stage 2, Grade B Periodontitis
RU2437095C1 (en) Method for determination of manganese toxicity in children being residents of technogenically-loaded territories
RU2546526C1 (en) Diagnostic technique for oxidative stress in children exposed to nickel from external environment
Hagan et al. Phobic anxiety and plasma levels of global oxidative stress in women
Barbosa Jr et al. A critical review of biomarkers used for monitoring human exposure to lead: advantages, limitations and future needs
JP6889439B2 (en) Radiation exposure determination method
Ting et al. Factors Associated With Irritant Reactions on Epicutaneous Patch Testing
US20250263772A1 (en) Test method for physical frailty, test reagent for physical frailty, method for screening therapeutic candidate substance for physical frailty, test melthod for mental frailty, test reagent for mental frailty, and method for screening therapeutic cnadidate substance for mental frailty
Lord et al. Autism spectrum disorders: general overview
Fan et al. The Association of Bone, Fingernail and Blood Manganese with Cognitive and Olfactory Function in Chinese Workers
RU2544480C1 (en) Method for prediction of arterial hypertension in adolescents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20181227

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191023

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200629

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201110

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201127

R150 Certificate of patent or registration of utility model

Ref document number: 6830578

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250